オリゴヌクレオチド合成市場：製品（医薬品、合成オリゴ（プライマー）、試薬）、タイプ（カスタム、設計済み）、用途（治療（ASO、siRNA）、研究（（PCR、シークエンス、診断））、エンドユーザー（医薬品、CROS、CMO）-2027年までの世界市場予測

Oligonucleotide Synthesis Market by Product (Drug, Synthesized Oligo (Primer), Reagents), Type (Custom, Predesigned), Application (Therapeutic (ASO, siRNA), Research ((PCR, Sequencing, Diagnostics)), End User (Pharma, CROS, CMOs) - Global Forecast to 2027

世界のオリゴヌクレオチド合成市場は、2022年の77億米ドルから2027年には167億米ドルに達し、予測期間中に16.8%のCAGRで推移すると予測されています。市場の成長は、腫瘍学などの主要な治療分野におけるオリゴヌ... もっと見る

出版社	出版年月	電子版価格	ページ数	図表数	言語
MarketsandMarkets マーケッツアンドマーケッツ	2022年11月11日	US$4,950 シングルユーザライセンスライセンス・価格情報注文方法はこちら	297	411	英語

サマリー

世界のオリゴヌクレオチド合成市場は、2022年の77億米ドルから2027年には167億米ドルに達し、予測期間中に16.8%のCAGRで推移すると予測されています。市場の成長は、腫瘍学などの主要な治療分野におけるオリゴヌクレオチドベースの治療法の臨床試験の進行が増加していることに起因しています。
"合成オリゴ市場、製品別ではプライマー部門が最も高い成長率に"
合成オリゴヌクレオチド市場の製品別セグメントは、プライマー、プローブ、DNAオリゴ、RNAオリゴ、BNA＆LNAオリゴなどその他の合成オリゴに分けられる。プライマーは、PCR、シーケンシング、遺伝子合成、クローニングなど幅広い用途に使用されるため、予測期間中に最も高い成長を示すと予想されます。
"治療用途別では、2021年のオリゴヌクレオチド合成市場において、アンチセンスオリゴヌクレオチドベースの治療分野が最大のシェアを占めている"
治療用途セグメントはさらに、アンチセンスオリゴヌクレオチドベースの治療法、siRNAオリゴヌクレオチドベースの治療法、CpGオリゴヌクレオチドベースの治療法に分類されます。2021年には、アンチセンスオリゴは現在臨床試験中の多くの治療の基礎を形成しているため、このセグメントの最大のシェアを占め、セグメントの成長を後押ししています。
Danaher Corporation（米国）、Thermo Fisher Scientific, Inc.（米国）、Merck KGaA（ドイツ）、LGC Limited（英国）、Maravai Life Sciences（米国）、Agilent Technologies, Inc（米国）、Eurofins Scientific（ドイツ）、株式会社カネカ（日本）、Biolegio B.V（オランダ）、Biolytic Lab Performance Inc（米国）、Microsynth AG（スイス）、ATDBio Ltd. (米国)、Twist Bios Inc. (米国)、Twist Bios Inc.(英国）、Twist Bioscience Corporation（米国）、Eton Bioscience, Inc（米国）、CSBIO（米国）、Tag Copenhagen A/S（デンマーク）、Biogen Inc（米国）、Sarepta Therapeutics, Inc（米国）、Ionis Pharmaceuticals, Inc（米国）、Alnylam Pharmaceuticals, Inc（米国）などの主要プレイヤーが市場に進出しています。

"アジア太平洋地域は、オリゴヌクレオチド合成市場で最高のCAGRを記録する"
アジア太平洋地域のオリゴヌクレオチド合成市場は、予測期間中に最も速い速度で発展すると予想されています。研究開発資金や研究活動の増加、製品の入手可能性の向上、外注費の減少などが、市場成長を促進する要因として挙げられます。
本レポートのために実施した主なインタビューは、以下のように分類されます。

- 回答者別供給側：80％、需要側：20
- 役職別管理職：45%、CXOおよびディレクターレベル：30%、経営幹部：25
- 地域別北米：20％、欧州：10％、アジア太平洋：55％、RoW：15
報告書に掲載されている企業一覧
- サーモフィッシャーサイエンティフィック社（米国）
- Merck KGaA (ドイツ)
- ダナハーコーポレーション（米国）
- LGC Limited（イギリス）
- マラバイ・ライフサイエンス（米国）
- アジレント・テクノロジー株式会社 (米国)
- ユーロフィンズサイエンティフィック（ドイツ）
- 株式会社カネカ (日本)
- バイオレギオB.V. （オランダ）
- Biolytic Lab Performance Inc.
- Microsynth AG（スイス）
- ATDBio Ltd.(イギリス)
- ツイストバイオサイエンス社（米国）
- イートン・バイオサイエンス社（米国）
- CSBIO（米国）
- Tag Copenhagen A/S（デンマーク）
- ジェネリバイオテック社（チェコ）
- Biocomma Limited（中国）
- 宏源生物技術有限公司（中国）
- 杭州製薬化工有限公司（中国）
- 東京化成工業株式会社（日本日本
- バイオジェン・インク（米国）
- Sarepta Therapeutics, Inc.（米国）
- Ionis Pharmaceuticals, Inc.（米国）
- Alnylam Pharmaceuticals, Inc.（米国）

調査対象
本レポートは、オリゴヌクレオチド合成市場の詳細な情報を提供します。製品、アプリケーション、エンドユーザー、地域などの異なるセグメントにおける市場規模と将来の成長性を推定することを目的としています。また、主要な市場プレイヤーの詳細な競合分析、企業プロファイル、最近の開発状況、主要な市場戦略も掲載しています。

レポート購入の主なメリット
本レポートは、オリゴヌクレオチド合成市場全体とそのサブセグメントに関する収益数の最も近い近似値を提供することで、市場リーダー/新規参入者の助けとなります。また、利害関係者が競争環境をより良く理解し、自社のビジネスを位置づけ、適切な市場参入戦略を立てるためのより多くの洞察を得るのに役立ちます。本レポートは、利害関係者が市場の脈絡を理解し、主要な市場促進要因、阻害要因、課題、動向、機会に関する情報を提供することを可能にするものです。

ページTOPに戻る

1 INTRODUCTION 49
1.1 STUDY OBJECTIVES 49
1.2 MARKET DEFINITION 49
1.2.1 INCLUSIONS AND EXCLUSIONS 50
1.3 MARKET SCOPE 51
1.3.1 MARKETS COVERED 51
1.3.2 YEARS CONSIDERED 52
1.4 CURRENCY CONSIDERED 52
1.5 LIMITATIONS 52
1.6 STAKEHOLDERS 53
1.7 SUMMARY OF CHANGES 53
2 RESEARCH METHODOLOGY 54
2.1 RESEARCH DATA 54
FIGURE 1 RESEARCH DESIGN 54
2.1.1 SECONDARY DATA 54
2.1.2 PRIMARY DATA 55
FIGURE 2 BREAKDOWN OF PRIMARIES 56
2.2 MARKET ESTIMATION METHODOLOGY 57
FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION (RESEARCH AND DIAGNOSTIC MARKET) 57
FIGURE 4 MARKET SIZE ESTIMATION- COMPANY REVENUE ANALYSIS-BASED ESTIMATION (THERAPEUTIC MARKET) 57
FIGURE 5 OLIGONUCLEOTIDE SYNTHESIS MARKET SIZE (USD MILLION) 58
FIGURE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: FINAL CAGR PROJECTIONS (2022−2027) 58
FIGURE 7 OLIGONUCLEOTIDE SYNTHES MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 59
FIGURE 8 OLIGONUCLEOTIDE SYNTHESIS: SEGMENTAL ASSESSMENT 60
2.2.1 INSIGHTS FROM PRIMARY EXPERTS 60
FIGURE 9 MARKET SIZE VALIDATION FROM PRIMARY SOURCES 60
2.3 DATA TRIANGULATION 61
FIGURE 10 DATA TRIANGULATION METHODOLOGY 61
2.4 STUDY ASSUMPTIONS 62
2.5 RISK ANALYSIS 62
3 EXECUTIVE SUMMARY 63
FIGURE 11 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2022 VS. 2027 (USD MILLION) 63
FIGURE 12 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2022 VS. 2027 (USD MILLION) 64
FIGURE 13 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2022 VS. 2027 (USD MILLION) 64
FIGURE 14 GEOGRAPHICAL SNAPSHOT OF OLIGONUCLEOTIDE SYNTHESIS MARKET 65
4 PREMIUM INSIGHTS 66
4.1 OLIGONUCLEOTIDE SYNTHESIS MARKET OVERVIEW 66
FIGURE 15 INCREASING USE OF SYNTHETIC OLIGOS TO DRIVE MARKET 66
4.2 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION AND COUNTRY (2021) 67
FIGURE 16 THERAPEUTIC APPLICATION SEGMENT ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2021 67
4.3 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY PRODUCT, 2022 VS. 2027 67
FIGURE 17 OLIGONUCLEOTIDE-BASED DRUGS SEGMENT TO DOMINATE MARKET IN 2027 67
4.4 OLIGONUCLEOTIDE SYNTHESIS MARKET SHARE, BY APPLICATION, 2022 68
FIGURE 18 THERAPEUTIC APPLICATION SEGMENT TO ACCOUNT FOR LARGEST MARKET SHARE IN 2022 68
4.5 OLIGONUCLEOTIDE SYNTHESIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 68
FIGURE 19 ASIA PACIFIC COUNTRIES TO WITNESS HIGHEST GROWTH DURING FORECAST PERIOD 68
5 MARKET OVERVIEW 69
5.1 INTRODUCTION 69
5.2 MARKET DYNAMICS 69
FIGURE 20 OLIGONUCLEOTIDE SYNTHESIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 69
5.2.1 DRIVERS 70
5.2.1.1 Increasing use of synthesized oligos in therapeutic applications 70
TABLE 1 FDA-APPROVED OLIGONUCLEOTIDE-BASED THERAPIES 70
FIGURE 21 ONGOING CLINICAL TRIALS BY TOP 10 THERAPEUTIC AREAS 71
5.2.1.2 Increasing government investments in synthetic biology and genome projects 71
5.2.1.3 Growing focus on personalized medicine 72
5.2.2 RESTRAINTS 72
5.2.2.1 Complexities associated with therapeutic oligos 72
5.2.3 OPPORTUNITIES 73
5.2.3.1 Increasing R&D investments by key players in emerging economies 73
5.2.4 CHALLENGES 74
5.2.4.1 Delivery of oligonucleotide drugs to specific targets 74
5.3 RANGES/SCENARIOS 75
FIGURE 22 SPECTRUM OF SCENARIOS BASED ON IMPACT OF UNCERTAINTIES ON GROWTH OF OLIGONUCLEOTIDE SYNTHESIS MARKET 75
5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 76
FIGURE 23 REVENUE SHIFT AND NEW REVENUE POCKETS 76

5.5 SUPPLY CHAIN ANALYSIS 76
FIGURE 24 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES 77
5.5.1 KEY INFLUENCERS 77
5.6 VALUE CHAIN ANALYSIS 78
FIGURE 25 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 78
5.7 ECOSYSTEM ANALYSIS 78
FIGURE 26 ECOSYSTEM ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS MARKET 78
5.7.1 ROLE IN ECOSYSTEM 79
5.8 TECHNOLOGICAL ANALYSIS 79
5.8.1 SOLID-PHASE SYNTHESIS 79
5.8.2 LIQUID-PHASE SYNTHESIS 79
5.9 INDICATIVE PRICING MODEL ANALYSIS 80
TABLE 2 PRICING ANALYSIS OF OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 80
5.10 TRADE DATA 81
TABLE 3 IMPORT DATA FOR OLIGONUCLEOTIDES, BY COUNTRY, 2016–2020 (USD THOUSAND) 81
5.11 REGULATORY ANALYSIS 84
5.11.1 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS 84
5.11.2 GOVERNMENT REGULATIONS FOR OLIGONUCLEOTIDE-BASED DRUGS: GOOD MANUFACTURING PRACTICES (GMP) 85
5.11.3 ISO 13485 85
5.11.4 IVD & ASR 85
5.12 PATENT ANALYSIS 86
FIGURE 27 TOP APPLICANTS & OWNERS (COMPANIES/INSTITUTIONS) FOR OLIGONUCLEOTIDE SYNTHESIS PATENTS (JANUARY 2012–OCTOBER 2022) 86
TABLE 4 INDICATIVE LIST OF PATENTS IN OLIGONUCLEOTIDE SYNTHESIS MARKET 87
5.13 PORTER’S FIVE FORCES ANALYSIS 88
TABLE 5 PORTER’S FIVE FORCES ANALYSIS 88
5.13.1 DEGREE OF COMPETITION 88
5.13.2 BARGAINING POWER OF SUPPLIERS 88
5.13.3 BARGAINING POWER OF BUYERS 88
5.13.4 THREAT OF SUBSTITUTES 88
5.13.5 THREAT OF NEW ENTRANTS 88
5.14 KEY CONFERENCES AND EVENTS IN 2022–2023 89
TABLE 6 OLIGONUCLEOTIDE SYNTHESIS MARKET: LIST OF CONFERENCES AND EVENTS 89
5.15 KEY STAKEHOLDERS AND BUYING CRITERIA 89
FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 89
5.16 KEY BUYING CRITERIA BY END USERS 90
FIGURE 29 BUYING CRITERIA OF END USERS FOR OLIGONUCLEOTIDE SYNTHESIS PRODUCTS 90
6 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT 91
6.1 INTRODUCTION 92
TABLE 7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 92
TABLE 8 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY REGION, 2020–2027 (USD MILLION) 92
TABLE 9 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 10 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 11 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION) 93
TABLE 12 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PRODUCT, BY COUNTRY, 2020–2027 (USD MILLION) 94
6.2 OLIGONUCLEOTIDE-BASED DRUGS 94
6.2.1 OLIGONUCLEOTIDE-BASED DRUGS DOMINATED MARKET IN 2021 94
TABLE 13 OLIGONUCLEOTIDE-BASED THERAPIES 94
TABLE 14 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY REGION, 2020–2027 (USD MILLION) 95
TABLE 15 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 95
TABLE 16 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 17 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 96
TABLE 18 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR OLIGONUCLEOTIDE-BASED DRUGS, BY COUNTRY, 2020–2027 (USD MILLION) 97
6.3 SYNTHESIZED OLIGONUCLEOTIDES 97
TABLE 19 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 97
TABLE 20 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 21 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 22 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 98
TABLE 23 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 99
6.3.1 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY PRODUCT 99
TABLE 24 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 99
6.3.1.1 Primers 100
6.3.1.1.1 Increasing applications for oligo primers in DNA sequencing and molecular diagnostics to drive segment 100
TABLE 25 PRIMERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 100
TABLE 26 PRIMERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 27 PRIMERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 28 PRIMERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 101
TABLE 29 PRIMERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 102
6.3.1.2 Probes 102
6.3.1.2.1 Probes to detect various infectious agents and altered DNA/RNA sequences 102
TABLE 30 PROBES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 103
TABLE 31 PROBES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 103
TABLE 32 PROBES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 33 PROBES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 104
TABLE 34 PROBES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 105
6.3.1.3 DNA oligos 105
6.3.1.3.1 Innovations in DNA oligos to eliminate time-consuming PCR and drive segment 105
TABLE 35 DNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 105
TABLE 36 DNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 37 DNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 38 DNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 106
TABLE 39 DNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 107
6.3.1.4 RNA oligos 107
6.3.1.4.1 RNA oligos to be used as molecular diagnostic tools 107
TABLE 40 RNA OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 107
TABLE 41 RNA OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 42 RNA OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 43 RNA OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 108
TABLE 44 RNA OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 109
6.3.1.5 Other synthesized oligonucleotides 109
TABLE 45 OTHER SYNTHESIZED OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 110
TABLE 46 OTHER SYNTHESIZED OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 110
TABLE 47 OTHER SYNTHESIZED OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 48 OTHER SYNTHESIZED OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 111
TABLE 49 OTHER SYNTHESIZED OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 112
6.3.2 SYNTHESIZED OLIGONUCLEOTIDES MARKET, BY TYPE 112
TABLE 50 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 112
6.3.2.1 Custom oligonucleotides 112
6.3.2.1.1 Surge in demand in clinical and preclinical studies to propel segment 112
TABLE 51 CUSTOM OLIGONUCLEOTIDES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 113
TABLE 52 CUSTOM OLIGONUCLEOTIDES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 113
TABLE 53 CUSTOM OLIGONUCLEOTIDES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 54 CUSTOM OLIGONUCLEOTIDES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 114
TABLE 55 CUSTOM OLIGONUCLEOTIDES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 114

6.3.2.2 Predesigned oligos 115
6.3.2.2.1 Predesigned oligos to be used in routine research applications, such as PCR and sequencing 115
TABLE 56 PREDESIGNED OLIGOS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY REGION, 2020–2027 (USD MILLION) 115
TABLE 57 PREDESIGNED OLIGOS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 115
TABLE 58 PREDESIGNED OLIGOS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 116
TABLE 59 PREDESIGNED OLIGOS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 116
TABLE 60 PREDESIGNED OLIGOS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY COUNTRY, 2020–2027 (USD MILLION) 116
6.4 REAGENTS 117
6.4.1 GROWING APPLICATIONS OF OLIGOS IN SEQUENCING, DRUG DESIGN, AND GENE SYNTHESIS TO PROPEL MARKET 117
TABLE 61 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY REGION, 2020–2027 (USD MILLION) 117
TABLE 62 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 63 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 64 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 118
TABLE 65 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR REAGENTS, BY COUNTRY, 2020–2027 (USD MILLION) 119
6.5 EQUIPMENT 119
6.5.1 TECHNOLOGICAL INNOVATIONS IN OLIGONUCLEOTIDE SYNTHESIZERS TO STIMULATE MARKET 119
TABLE 66 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY REGION, 2020–2027 (USD MILLION) 120
TABLE 67 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 120
TABLE 68 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 69 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 121
TABLE 70 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR EQUIPMENT, BY COUNTRY, 2020–2027 (USD MILLION) 121
7 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION 122
7.1 INTRODUCTION 123
TABLE 71 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
TABLE 72 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 123
TABLE 73 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY REGION, 2020–2027 (USD MILLION) 124
TABLE 74 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 124
TABLE 75 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 76 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 125
TABLE 77 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 125
7.2 THERAPEUTIC APPLICATIONS 126
TABLE 78 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 126
TABLE 79 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATION, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 80 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 81 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 127
TABLE 82 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 128
7.2.1 THERAPEUTIC APPLICATIONS MARKET, BY TYPE 128
TABLE 83 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 128
7.2.1.1 Antisense oligonucleotide-based therapies 129
7.2.1.1.1 Antisense oligos to form basis of therapies in clinical trials 129
TABLE 84 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 129
TABLE 85 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 129
TABLE 86 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 87 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 130
TABLE 88 ANTISENSE OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 131
7.2.1.2 siRNA oligonucleotide-based therapies 131
7.2.1.2.1 Ease of drug target identification with bioinformatics to boost segment 131
TABLE 89 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 132
TABLE 90 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 132
TABLE 91 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 92 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 133
TABLE 93 SIRNA OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 134
7.2.1.3 CpG oligonucleotide-based therapies 134
7.2.1.3.1 CpG ODNs to show significant potential for variety of disease treatments, including cancer 134
TABLE 94 CPG OLIGONUCLEOTIDE-BASED THERAPIES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 134
TABLE 95 CPG OLIGONUCLEOTIDE-BASED THERAPIES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 96 CPG OLIGONUCLEOTIDE-BASED THERAPIES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 97 CPG OLIGONUCLEOTIDE-BASED THERAPIES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 135
TABLE 98 CPG OLIGONUCLEOTIDE-BASED THERAPIES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 136
7.2.2 THERAPEUTIC APPLICATIONS MARKET, BY DISEASE TYPE 136
TABLE 99 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 136
7.2.2.1 Neurological disorders 136
7.2.2.1.1 Neurological disorders dominated market by disease type in 2020 136
TABLE 100 NEUROLOGICAL DISORDERS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 137
TABLE 101 NEUROLOGICAL DISORDERS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 137
TABLE 102 NEUROLOGICAL DISORDERS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 103 NEUROLOGICAL DISORDERS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 138
TABLE 104 NEUROLOGICAL DISORDERS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 139

7.2.2.2 Infectious diseases 139
7.2.2.2.1 Antisense therapies and oligonucleotide aptamers to be significant in treatment and diagnosis of infectious diseases 139
TABLE 105 INFECTIOUS DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 140
TABLE 106 INFECTIOUS DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 107 INFECTIOUS DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 140
TABLE 108 INFECTIOUS DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 141
TABLE 109 INFECTIOUS DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 141
7.2.2.3 Other diseases 141
TABLE 110 OTHER DISEASES: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 142
TABLE 111 OTHER DISEASES: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 142
TABLE 112 OTHER DISEASES: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 113 OTHER DISEASES: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 143
TABLE 114 OTHER DISEASES: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 144
7.3 RESEARCH APPLICATIONS 144
TABLE 115 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 144
TABLE 116 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 145
TABLE 117 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 145
TABLE 118 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 146
TABLE 119 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 146
TABLE 120 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 146
7.3.1 PCR 147
7.3.1.1 Increasing use of PCR in research to drive market 147
TABLE 121 PCR: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 147
TABLE 122 PCR: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 147
TABLE 123 PCR: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 124 PCR: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 148
TABLE 125 PCR: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 148
7.3.2 SEQUENCING 149
7.3.2.1 Advancements in technologies and low cost of DNA sequencing to boost segment 149
TABLE 126 SEQUENCING: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 149
TABLE 127 SEQUENCING: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 128 SEQUENCING: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 129 SEQUENCING: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 150
TABLE 130 SEQUENCING: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 151
7.3.3 OTHER RESEARCH APPLICATIONS 151
TABLE 131 OTHER RESEARCH APPLICATIONS: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 152
TABLE 132 OTHER RESEARCH APPLICATIONS: NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 133 OTHER RESEARCH APPLICATIONS: EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 152
TABLE 134 OTHER RESEARCH APPLICATIONS: ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 153
TABLE 135 OTHER RESEARCH APPLICATIONS: LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 153
7.4 DIAGNOSTIC APPLICATIONS 153
7.4.1 GROWING FIELDS OF MOLECULAR DIAGNOSTICS (MDX) AND IN VITRO DIAGNOSTICS (IVD) TO AUGMENT SEGMENT 153
TABLE 136 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2020–2027 (USD MILLION) 154
TABLE 137 NORTH AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 154
TABLE 138 EUROPE OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 139 ASIA PACIFIC OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 155
TABLE 140 LATIN AMERICA OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2020–2027 (USD MILLION) 156

8 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER 157
8.1 INTRODUCTION 158
TABLE 141 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 158
TABLE 142 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY REGION, 2020–2027 (USD MILLION) 158
TABLE 143 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 144 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 145 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION) 159
TABLE 146 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR END USER, BY COUNTRY, 2020–2027 (USD MILLION) 160
8.2 HOSPITALS 160
8.2.1 INCREASING FDA-APPROVALS FOR OLIGONUCLEOTIDE-BASED DRUGS TO STIMULATE MARKET 160
TABLE 147 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY REGION, 2020–2027 (USD MILLION) 161
TABLE 148 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 161
TABLE 149 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 161
TABLE 150 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 162
TABLE 151 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR HOSPITALS, BY COUNTRY, 2020–2027 (USD MILLION) 162
8.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 162
8.3.1 GROWING APPLICATIONS OF OLIGOS IN DRUG DISCOVERY AND THERAPEUTICS TO DRIVE SEGMENT 162
TABLE 152 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2020–2027 (USD MILLION) 163
TABLE 153 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 163
TABLE 154 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 155 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 164
TABLE 156 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2020–2027 (USD MILLION) 164
8.4 DIAGNOSTIC LABORATORIES 165
8.4.1 INCREASING SIGNIFICANCE OF OLIGOS IN MOLECULAR DIAGNOSTICS TO STIMULATE GROWTH 165
TABLE 157 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2020–2027 (USD MILLION) 165
TABLE 158 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 166
TABLE 159 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 166
TABLE 160 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 166
TABLE 161 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2020–2027 (USD MILLION) 167
8.5 CONTRACT RESEARCH ORGANIZATIONS & CONTRACT MANUFACTURING ORGANIZATIONS 167
8.5.1 WIDE RANGE OF CUSTOMIZED OLIGO SERVICES TO AID GROWTH 167
TABLE 162 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY REGION, 2020–2027 (USD MILLION) 168
TABLE 163 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 164 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 165 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 169
TABLE 166 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR CROS & CMOS, BY COUNTRY, 2020–2027 (USD MILLION) 169
8.6 ACADEMIC RESEARCH & INSTITUTES 169
8.6.1 ACADEMIC AND GOVERNMENT RESEARCHERS TO USE OLIGOS FOR GENOMIC TECHNOLOGIES 169
TABLE 167 OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2020–2027 (USD MILLION) 170
TABLE 168 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 170
TABLE 169 EUROPE: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 170 ASIA PACIFIC: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 171
TABLE 171 LATIN AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2020–2027 (USD MILLION) 171
9 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION 172
9.1 INTRODUCTION 173
TABLE 172 OLIGONUCLEOTIDE SYNTHESIS MARKET, BY REGION, 2020–2027 (USD MILLION) 173
9.2 NORTH AMERICA 174
FIGURE 30 NORTH AMERICA: MARKET SNAPSHOT 174
TABLE 173 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 175
TABLE 174 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 175
TABLE 175 NORTH AMERICA: SYNTHESIZES OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 175
TABLE 176 NORTH AMERICA: SYNTHESIZED OLIGONUCLEOTIDE SYNTHESIS MARKET, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 177 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 176
TABLE 178 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 179 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 177
TABLE 180 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 177
TABLE 181 NORTH AMERICA: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 177
9.2.1 US 178
9.2.1.1 Government initiatives and strategic developments to drive market 178
TABLE 182 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 179
TABLE 183 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY PRODUCT, 2020–2027 (USD MILLION) 179
TABLE 184 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR SYNTHESIZED OLIGONUCLEOTIDES, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 185 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY APPLICATION, 2020–2027 (USD MILLION) 180
TABLE 186 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 180
TABLE 187 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR THERAPEUTIC APPLICATIONS, BY DISEASE TYPE, 2020–2027 (USD MILLION) 180
TABLE 188 US: OLIGONUCLEOTIDE SYNTHESIS MARKET FOR RESEARCH APPLICATIONS, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 189 US: OLIGONUCLEOTIDE SYNTHESIS MARKET, BY END USER, 2020–2027 (USD MILLION) 181

ページTOPに戻る

Table of Contents

Summary

The global oligonucleotide synthesis market is projected to reach USD 16.7 billion by 2027 from USD 7.7 billion in 2022, at a CAGR of 16.8% during the forecast period. Market growth can be attributed to the increasing ongoing clinical trials for oligonucleotide-based therapies for leading therapeutic areas such as oncology.
“The primers segment will grow at the highest rate in the synthesized oligos market, by product”
By product, the synthesized oligonucleotides market segment is divided into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos. Primers are expected to show the highest growth over the forecast period owing to their wide applications in PCR, sequencing, gene synthesis, and cloning.
“By therapeutic application, the antisense oligonucleotide-based therapies segment accounted for the largest share of the oligonucleotide synthesis market in 2021”
The therapeutic application segment is further segmented into antisense oligonucleotide-based therapies, siRNA oligonucleotide-based therapies, and CpG oligonucleotide-based therapies. In 2021, antisense oligos accounted for the largest share of this segment as they form the basis of many therapies that are currently in clinical trials, thus boosting segment growth.
Danaher Corporation (US), Thermo Fisher Scientific, Inc. (US), Merck KGaA (Germany), LGC Limited (UK), Maravai Life Sciences (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Germany), Kaneka Corporation (Japan), Biolegio B.V. (Netherlands), Biolytic Lab Performance Inc. (US), Microsynth AG (Switzerland), ATDBio Ltd. (UK), Twist Bioscience Corporation (US), Eton Bioscience, Inc. (US), CSBIO (US), Tag Copenhagen A/S (Denmark), Biogen Inc. (US), Sarepta Therapeutics, Inc. (US), Ionis Pharmaceuticals, Inc. (US), and Alnylam Pharmaceuticals, Inc. (US) are some of the major players operating in the market.

“Asia Pacific region will register a highest CAGR in the oligonucleotide synthesis market”
The market for oligonucleotide synthesis in Asia Pacific is anticipated to develop at the fastest rate during the forecast period. Growing R&D funding and research activity, increased product availability and decreased outsourcing costs are some of the factors that are likely to propel market growth.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 80% and Demand Side - 20%
• By Designation: Managers- 45%, CXOs, and Director level - 30%, and Executives - 25%
• By Region: North America -20%, Europe -10%, Asia-Pacific -55%, RoW -15%
List of Companies Profiled in the Report:
• Thermo Fisher Scientific, Inc. (US)
• Merck KGaA (Germany)
• Danaher Corporation (US)
• LGC Limited (UK)
• Maravai Life Sciences (US)
• Agilent Technologies, Inc. (US)
• Eurofins Scientific (Germany)
• Kaneka Corporation (Japan)
• Biolegio B.V. (Netherlands)
• Biolytic Lab Performance Inc. (US)
• Microsynth AG (Switzerland)
• ATDBio Ltd. (UK)
• Twist Bioscience Corporation (US)
• Eton Bioscience, Inc. (US)
• CSBIO (US)
• Tag Copenhagen A/S (Denmark)
• Generi Biotech (Czech Republic)
• Biocomma Limited (China)
• Hongene Biotech Corporation (China)
• Hangzhou pharm &chem Co., Ltd (China)
• Tokyo Chemical Industry Co., Ltd. (Japan)
• Biogen Inc. (US)
• Sarepta Therapeutics, Inc. (US)
• Ionis Pharmaceuticals, Inc. (US)
• Alnylam Pharmaceuticals, Inc. (US)

Research Coverage:
This report provides a detailed picture of the oligonucleotide synthesis market. It aims to estimate the market’s size and future growth potential across different segments such as the product, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players and their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall oligonucleotide synthesis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market’s pulse and provide information on the key market drivers, restraints, challenges, trends, and opportunities.

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（oligonucleotide）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

マーケッツアンドマーケッツ（MarketsandMarkets）は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る

調査レポートの納品までの日数はどの程度ですか?

在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。

注文の手続きはどのようになっていますか?

1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。

お支払方法の方法はどのようになっていますか?

納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
お客様よりデータリソース社へ（通常は円払い）の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。

データリソース社はどのような会社ですか?

当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。

サマリー

目次

Summary

Table of Contents

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

本レポートと同分野（その他）の最新刊レポート

MarketsandMarkets 社の最新刊レポート

本レポートと同じKEY WORD（oligonucleotide）の最新刊レポート

よくあるご質問

MarketsandMarkets社はどのような調査会社ですか?

調査レポートの納品までの日数はどの程度ですか?

注文の手続きはどのようになっていますか?

お支払方法の方法はどのようになっていますか?

データリソース社はどのような会社ですか?